Has Ramaswamy Govindan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,306 in general payments to Ramaswamy Govindan, MD across 18 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ramaswamy Govindan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ramaswamy Govindan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ramaswamy Govindan, MD

Medical Oncology · Saint Louis, MONPI 1023034261

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Amgen at 49.7% of the total. Reporting peaked in 2019 at $10,377 and has fallen 98.6% since, to $149 in 2024.

$16,306in general payments, 2019–2025

Across 18 payments — averaging $905.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$8K
Janssen Global Services, LLC$3K
E.r. Squibb & Sons, L.L.C.$2K
Genentech, Inc.$2K
Ipsen Biopharmaceuticals, Inc$2K
Merck$632
plus $210 from 3 others

$16,391,622in research payments, 2019–2025

Across 255 payments — averaging $64,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$14.5M
Janssen Research & Development, LLC$637K
AbbVie$303K
E.r. Squibb & Sons, L.L.C.$273K
Merck$270K
GSK$229K
plus $159K from 6 others

What the payments were for

Consulting fees$6,95943%
Travel & lodging$7,42446%
Food & beverage$4233%
Education$1,5009%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	6	$8,105
Janssen Global Services, LLC	1	$2,500
E.r. Squibb & Sons, L.L.C.	1	$1,704
Genentech, Inc.	1	$1,655
Ipsen Biopharmaceuticals, Inc	1	$1,500
Merck	4	$632
Genmab U.S., Inc.	2	$149
F. Hoffmann-la Roche AG	1	$48
EMD Serono, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPDIVO$1,704
TECENTRIQ$1,655
ONIVYDE$1,500

How this compares

$16,306 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024

$916,267

Medicare patients

246

Services billed

25,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TagrissoOsimertinib Mesylate	36	$689,868
EliquisApixaban	47	$28,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	13	$8,787
Enoxaparin Sodium	16	$4,364
OxycontinOxycodone Hcl	21	$4,167
Prochlorperazine Maleate	42	$1,758
Dexamethasone	65	$747
Albuterol Sulfate HfaAlbuterol Sulfate	20	$554
Oxycodone Hcl	27	$536
Ondansetron Hcl	23	$509
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	12	$439
Gabapentin	15	$322
Potassium Chloride	17	$204
Omeprazole	18	$197
Levothyroxine Sodium	36	$178

Paid to pharmacies, not to this prescriber.

Other medical oncology in Saint Louis

Brad KahlSaint Louis$336K
Russell PachynskiSaint Louis$226K
Mark SchroederSaint Louis$198K
George AnsstasSaint Louis$189K
Ravi VijSaint Louis$153K
Douglas AdkinsSaint Louis$141K
Milan ChhedaSaint Louis$105K
Maurice WillisSaint Louis$101K
Moh'd KhushmanSaint Louis$84K
Camille AbboudSaint Louis$70K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →